A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02494778. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients With Huntington's Disease (Open PRIDE-HD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to collect and assess long term data on the safety, tolerability, and efficacy of pridopidine in patients with Huntington's disease (HD).
Study identification
- NCT ID
- NCT02494778
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 248 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 21 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 24, 2015 (Actual)
- Primary completion
- Jan 12, 2018 (Actual)
- Completion
- Jan 12, 2018 (Actual)
- Last update posted
- Sep 17, 2021
2015 – 2018
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 12204 | Los Angeles | California | 90095 | — |
| Teva Investigational Site 12201 | Englewood | Colorado | 80113 | — |
| Teva Investigational Site 12196 | Washington D.C. | District of Columbia | 20007 | — |
| Teva Investigational Site 12206 | Baltimore | Maryland | 21287 | — |
| Teva Investigational Site 12200 | Manhasset | New York | 11030 | — |
| Teva Investigational Site 12203 | New York | New York | 10032 | — |
| Teva Investigational Site 12198 | Rochester | New York | 14618 | — |
| Teva Investigational Site 12211 | Winston-Salem | North Carolina | 27157 | — |
| Teva Investigational Site 12209 | Pittsburgh | Pennsylvania | 15213 | — |
| Teva Investigational Site 12208 | Salt Lake City | Utah | 84108 | — |
| Teva Investigational Site 12210 | Richmond | Virginia | 23230 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02494778, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 17, 2021 · Synced Nov 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.